- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.04. | TELOMIR PHARMACEUTICALS, INC.: Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C. | 39 | GlobeNewswire (Europe) | Telomir-1 elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase that protects the DNA and genetic material in chromosomes to combat aging Demonstrated... ► Artikel lesen | |
| 12.04. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.04. | TELOMIR PHARMACEUTICALS, INC.: Telomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, ... | 1 | GlobeNewswire (USA) | ||
| 29.03. | Telomir Pharmaceuticals, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.03. | TELOMIR PHARMACEUTICALS, INC.: Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines | 67 | GlobeNewswire (Europe) | Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases This study is believed to be the first and only known study focused... ► Artikel lesen | |
| 22.03. | TELOMIR PHARMACEUTICALS, INC.: Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th | 3 | GlobeNewswire (USA) | ||
| 14.03. | TELOMIR PHARMACEUTICALS, INC.: Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate's Potential in DNA Age Reversal Science | 204 | GlobeNewswire (Europe) | BALTIMORE, March 14, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) ("Telomir" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
| 07.03. | TELOMIR PHARMACEUTICALS, INC.: Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference | 1 | GlobeNewswire (USA) | ||
| 05.03. | TELOMIR PHARMACEUTICALS, INC.: Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal | 1 | GlobeNewswire (USA) | ||
| 14.02. | Telomir Pharmaceuticals sold $7 million IPO in 5 days | 4 | Investing.com | ||
| 09.02. | Telomir Pharmaceuticals stock falls 29% following $7M IPO | 2 | Seeking Alpha | ||
| 09.02. | Metagenomi, Telomir head to Nasdaq this morning in double test case for preclinical IPOs | 1 | FierceBiotech | ||
| 09.02. | Telomir Pharma Prices IPO Of 1 Mln Shares At $7.00/shr | 766 | AFX News | WASHINGTON (dpa-AFX) - Telomir Pharmaceuticals Inc., a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, is developing Telomir-1 as the... ► Artikel lesen | |
| 09.02. | Hemochromatosis drug developer Telomir Pharmaceuticals prices IPO at $7 | - | Renaissance Capital | ||
| 08.02. | Telomir Pharmaceuticals announces pricing of initial public offering | - | Seeking Alpha | ||
| 08.02. | Telomir Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering | 98 | GlobeNewswire (Europe) | BALTIMORE, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, is developing Telomir-1... ► Artikel lesen | |
| 06.02. | Telomir Pharmaceuticals, Inc. - 8-A12B, Registration of securities | - | SEC Filings | ||
| 03.01. | Telomir Pharmaceuticals, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 14.12.23 | Telomir Pharmaceuticals Announces 1M Share IPO at $7/sh | 1 | Investing.com | ||
| 14.12.23 | Small molecule biotech Telomir Pharmaceuticals sets terms for $7 million IPO | 1 | Renaissance Capital |
Seite:
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,940 | +0,90 % | Ihre wichtigsten Termine: Heute im Fokus: Zahlen von Porsche AG, Philips, Qiagen, Vivendi und Bawag Group | © Foto: Porsche AG NewsroomGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:55... ► Artikel lesen | |
| EVOTEC | 9,760 | -1,36 % | Evotec Aktie: Hoffnung trotz Kurssturz? | Die Evotec-Aktie befindet sich mit einem aktuellen Kurs von 9,27 € und einer Veränderung von 1,78 % innerhalb der letzten Woche weiterhin in einer schwierigen Lage. Nach dem dramatischen Einbruch um... ► Artikel lesen | |
| MORPHOSYS | 66,65 | +0,83 % | Flut an Quartalszahlen: So reagiert der DAX - Außerdem im Fokus: Adidas und MorphoSys | Am Dienstag sind eine ganze Fülle von wichtigen Quartalszahlen präsentiert worden. Wie reagiert der deutsche Leitindex darauf? Außerdem im Fokus: Adidas und MorphoSys. Die Anleger am deutschen Aktienmarkt... ► Artikel lesen | |
| AMGEN | 291,00 | +12,07 % | Amgen Aktie: Revolutionäre Therapie gegen Schilddrüsenaugenerkrankung | Der Biotechnologie-Konzern Amgen hat kürzlich Pläne bekannt gegeben, eine Zulassung für sein neuestes Medikament zur Behandlung einer schweren Autoimmunerkrankung bei der Europäischen Arzneimittel-Agentur... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,760 | -0,34 % | (RXRX) - Analyzing Recursion Pharmaceuticals' Short Interest | ||
| JANUX THERAPEUTICS | 63,97 | +2,47 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
| BIONTECH | 86,10 | +0,53 % | BioNTech Aktie: Schwankung nach Aktien-Blase | Die BioNTech Aktie steht nach einer Woche mit gemischten Signalen bei einem Preis von 81,5 €, was einem Zuwachs von 0,8% entspricht. Dies könnte auf die üblichen Handelsschwankungen zurückzuführen sein... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 44,840 | +3,51 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates | - Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter - - Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors... ► Artikel lesen | |
| CG ONCOLOGY | 34,895 | -11,66 % | CG Oncology Inc.: Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | - Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 10,275 | +11,75 % | Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024.
"We are excited... ► Artikel lesen | |
| DYNE THERAPEUTICS | 26,580 | +2,39 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights | - Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 - WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne... ► Artikel lesen | |
| BEAM THERAPEUTICS | 23,150 | +1,94 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| MODERNA | 114,06 | -2,61 % | Opening Bell: Bitcoin, Apple, Moderna, Pfizer, NIO, Tesla, Peloton | Die Fed hat gestern nicht an der Zinsschraube gedreht. Sie bleiben bei 5,25 bis 5,5 Prozent. Zudem machte Powell klar, dass der nächste Zinsschritt sehr wahrscheinlich keine Zinserhöhung sein werde.... ► Artikel lesen | |
| RANI THERAPEUTICS | 7,080 | +11,15 % | Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update | - Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Announced Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 26,620 | +4,07 % | Navigating 7 Analyst Ratings For Avidity Biosciences |
TELOMIR PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,500 (-7,58 %) liegt der Kurs bei 6,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
